John Schoonmaker, DO
Family Medicine · Menifee, CANPI 1841231537
Payments from drug & device makers
Across 123 payments — averaging $20.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$519
- Novo Nordisk$383
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$323
- Pfizer$141
- AstraZeneca$138
- Lilly USA, LLC$135
- plus $940 from 25 others
What the payments were for
- Food & beverage$2,579100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 30 | $519 |
| Novo Nordisk | 18 | $383 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $323 |
| Pfizer | 7 | $141 |
| AstraZeneca | 7 | $138 |
| Lilly USA, LLC | 7 | $135 |
| GSK | 4 | $106 |
| Eisai Inc. | 5 | $97 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 3 | $60 |
| Amgen(2 entities) | 3 | $58 |
| Abbott | 2 | $45 |
| Exact Sciences | 2 | $42 |
| Johnson & Johnson | 2 | $40 |
| Corcept Therapeutics | 2 | $38 |
| Teva Pharmaceuticals USA, Inc. | 1 | $38 |
| Boehringer Ingelheim | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $36 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $36 |
| Merck | 2 | $34 |
| Novartis | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 1 | $29 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Esperion Therapeutics, Inc. | 2 | $26 |
| Hologic Sales And Service, LLC | 1 | $24 |
| Edwards Lifesciences | 1 | $23 |
| Bayer | 1 | $22 |
| Mylan Specialty L.p. | 1 | $21 |
| Boston Scientific | 1 | $20 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Sumitomo Pharma America, Inc. | 1 | $16 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
How this compares
$2,579 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 72 | $89,588 |
| JardianceEmpagliflozin | 64 | $82,296 |
| OzempicSemaglutide | 62 | $65,410 |
| JanuviaSitagliptin Phosphate | 45 | $49,311 |
| TrulicityDulaglutide | 31 | $46,276 |
| FarxigaDapagliflozin Propanediol | 28 | $35,967 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 52 | $35,324 |
| LinzessLinaclotide | 37 | $29,401 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 54 | $23,110 |
| TradjentaLinagliptin | 21 | $17,590 |
| Penicillamine | 12 | $17,098 |
| XareltoRivaroxaban | 13 | $16,277 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $15,328 |
| Spiriva RespimatTiotropium Bromide | 18 | $12,107 |
| EntrestoSacubitril/Valsartan | 12 | $12,056 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Combivent Respimat, Stiolto Respimat | $37 | $127,197126 claims |
| PfizerEliquis | $141 | $89,58872 claims |
| MerckJanuvia, Janumet, Belsomra | $34 | $69,31667 claims |
| Novo NordiskOzempic | $383 | $65,41062 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $138 | $51,17070 claims |
| Lilly USA, LLCTrulicity | $135 | $46,27631 claims |
| GSKTrelegy Ellipta | $106 | $35,32452 claims |
| AbbVieLinzess | $519 | $29,40137 claims |
| Johnson & JohnsonXarelto | $40 | $16,27713 claims |
| NovartisEntresto | $33 | $12,05612 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.
Other family medicine in Menifee
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
- Suzanne FussellOxnard$8.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.